title: Molecular analysis of retroviral transduction in chronic myelogenous leukemia.
abstract: We have developed a polymerase chain reaction (PCR) assay for detection of integrated retroviral transgenomes containing the neo G418 resistance gene in colonies (40 cells or more) grown in G418 selection after exposure to the neo-positive retrovirus LNL6. This assay also provides for simultaneous characterization of these colonies as belonging to a chronic myelogenous leukemic (bcr-abl positive) or nonleukemic population (bcr-abl negative). Using these techniques, we assessed transduction of the LNL6 retrovirus into the normal and leukemic cells of a blast-crisis chronic myelogenous leukemia (CML) patient. This work was designed to support the use of the LNL6 retroviral marker to help identify the origin of relapse after autologous marrow infusion. The data from these experiments show that the majority of CML blast crisis cells that, following exposure to the LNL6 virus, produce colonies under rigorous G418 selection are indeed transduced by the virus, as shown by the presence of the neo retroviral gene. Most of these colonies are also shown to be leukemic by PCR detection of the bcr-abl RNA. This demonstrates the feasibility of the study of CML marrow for retroviral marking. These procedures will be of use in establishing if relapse arises from leukemic blasts which contaminate purged autologous bone marrow infused following intensive therapy for leukemia.
authors.affiliation: Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
authors.forename: D
authors.initials: D
authors.lastname: Claxton
authors.forename: S P
authors.initials: SP
authors.lastname: Suh
authors.forename: M
authors.initials: M
authors.lastname: Filaccio
authors.forename: D
authors.initials: D
authors.lastname: Ellerson
authors.forename: E
authors.initials: E
authors.lastname: Gaozza
authors.forename: B
authors.initials: B
authors.lastname: Andersson
authors.forename: M
authors.initials: M
authors.lastname: Brenner
authors.forename: C
authors.initials: C
authors.lastname: Reading
authors.forename: A
authors.initials: A
authors.lastname: Feinberg
authors.forename: R
authors.initials: R
authors.lastname: Moen
mesh_terms: D001483:Base Sequence; D014408:Biomarkers, Tumor / Q000032:analysis; D001752:Blast Crisis / Q000473:pathology* / Q000601:surgery; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation; D004352:Drug Resistance, Microbial; D016044:Fusion Proteins, bcr-abl / Q000032:analysis*; D005819:Genetic Markers; D005822:Genetic Vectors; D006801:Humans; D019868:Kanamycin Kinase; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology* / Q000601:surgery; D008969:Molecular Sequence Data; D009355:Neomycin / Q000494:pharmacology; D009364:Neoplasm Recurrence, Local; D014411:Neoplastic Stem Cells / Q000378:metabolism / Q000473:pathology*; D010770:Phosphotransferases / Q000032:analysis* / Q000235:genetics; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000032:analysis; D012334:RNA, Neoplasm / Q000032:analysis; D011994:Recombinant Proteins / Q000032:analysis* / Q000235:genetics; D012190:Retroviridae / Q000235:genetics*; D014161:Transduction, Genetic; D014182:Transplantation, Autologous; D014407:Tumor Cells, Cultured
chemical_list: D014408:Biomarkers, Tumor; D005819:Genetic Markers; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D011994:Recombinant Proteins; D010770:Phosphotransferases; D019868:Kanamycin Kinase; D016044:Fusion Proteins, bcr-abl; D009355:Neomycin